Seattle Genetics Earnings: Waiting on ECHELON

Seattle Genetics Earnings: Waiting on ECHELON


With modest growth for Adcetris, its only drug on the market, investors should be focused on Seattle Genetics' pipeline and clinical trials that could further expand sales of Adcetris. Sales of Adcetris increased 12% year over year in the fourth quarter.



from Biotech News